Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan

Shao, Yu-Hsuan JoniYu-Hsuan JoniShaoJIAN-HUA HONGCHUN-KAI CHENCHAO-YUAN HUANG2023-12-202023-12-202023-1213657852https://scholars.lib.ntu.edu.tw/handle/123456789/638029The impact of gonadotropin-releasing hormone (GnRH) antagonist and agonist (GnRHa) treatment on cardiovascular disease (CVD) risk in prostate cancer (PCa) remains inconclusive due to conflicting findings. We compared the effects of GnRH antagonist and GnRHa treatments on CVD risk in patients with PCa and pre-existing CVD, in a Taiwan population-based database.en[SDGs]SDG3Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwanjournal article10.1038/s41391-022-00555-0356622912-s2.0-85131303777https://api.elsevier.com/content/abstract/scopus_id/85131303777